CMR in the Assessment of Cardiac Masses

Esposito, Antonio; Cobelli, Francesco De; Ironi, Gabriele; Marra, Paolo; Canu, Tamara; Mellone, Renata; Maschio, Alessandro Del

doi:10.1016/j.jcmg.2014.08.002

Cited by 32 publications

(23 citation statements)

References 3 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…We show that cardiac sarcomas and lymphomas have significantly worse survival compared with similar cancers of extracardiac origin, suggesting that any cardiac involvement, whether primary or metastatic, carries worse prognosis. It further implies that patients with extracardiac malignancies of histopathology types that affect the heart more commonly such as angiosarcomas and diffuse large B-cell lymphoma may need to be screened for cardiac involvement with echocardiography, 38 cardiac magnetic resonance imaging, 39 or cardiac positron emission tomography 40 at diagnosis. This likely does not apply to mesotheliomas because they have similarly poor survival regardless of location.…”

Section: Discussionmentioning

confidence: 99%

Characteristics and Survival of Malignant Cardiac Tumors

et al. 2015

View full text Add to dashboard Cite

Background-The aim of this study was to investigate the incidence, histopathology, demographics, and survival associated with primary malignant cardiac tumors (PMCTs). Methods and Results-We queried the Surveillance, Epidemiology and End Results (SEER) 18 registry from the National Cancer Institute for all PMCTs diagnosed from 1973 to 2011. We describe PMCT histopathology and incidence, comparing characteristics and survival of these patients with those of patients with extracardiac malignancies of similar histopathology. From a total of 7 384 580 cases of cancer registered in SEER, we identified 551 PMCTs (0.008%). The incidence of PMCT diagnosis is 34 cases per 100 million persons and has increased over time (25.1 in 1973-1989, 30.2 in 1990-1999, and 46.6 in 2000-2011). Most patients are female (54.1%) and white (78.6%) with median age at diagnosis of 50 years. The most common PMCTs are sarcomas (n=357, 64.8%), followed by lymphomas (n=150, 27%) and mesotheliomas (n=44, 8%). Most patients are diagnosed with tissue sample (96.8%). Although use of chemotherapy is not documented in SEER, 19% of patients received radiation and 44% had surgery. After a median follow-up of 80 months, 413 patients had died. The 1-, 3-, and 5-year survival rates were 46%, 22%, and 17% and have improved over the eras, with 1-, 3-, and 5-year survival rates of 32%, 17%, and 14% for 1973 to 1989 and 50%, 24%, and 19% for 2000 to 2011 (P=0.009). Cardiac sarcomas and mesotheliomas are the most lethal PMCTs, with 1-, 3-, 5-year survival rates of 47%, 16%, and 11% and of 51%, 26%, and 23% compared with 59%, 41%, and 34% for lymphomas, respectively (log rank test P<0.001). Patients with cardiac lymphomas and sarcomas are younger and have worse survival than patients with extracardiac disease of similar histopathology (P<0.001). Conclusions-PMCTs are extremely rare and continue to be associated with poor prognosis. Over the past 5 decades, the incidence and survival of patients diagnosed with PMCT appear to have increased.

show abstract

Section: Discussionmentioning

confidence: 99%

Characteristics and Survival of Malignant Cardiac Tumors

et al. 2015

View full text Add to dashboard Cite

show abstract

“…Using 3-D reconstructing technology with CT or MRI, surgeons can assess the location, size and pedicle of the tumor intuitively before surgery, which was greatly helpful in guiding the approach of the resection of the tumor in surgery (9,10). Several cases of our series with giant mass in the heart showed great difficulties before surgery, by simulating steps of surgery outside the body using 3-D reconstructing technology, we successfully complete the giant mass resection.…”

mentioning

confidence: 89%

“…Non-invasive procedures, such as echocardiography, computed tomography (CT), and magnetic resonance imaging (MRI) of the heart, are commonly used in helping diagnose cardiac tumors (9,10). Surgical treatment is advisable for patients to remove the tumor to prevent lifethreatening events occurring.…”

Section: Introductionmentioning

confidence: 99%

Surgical treatment of cardiac tumors: a 5-year experience from a single cardiac center

Liang

Shen

et al. 2016

J. Thorac. Dis.

View full text Add to dashboard Cite

Background: Cardiac tumors are rare but manifested with various clinical presentations and often cause unexpected symptoms or sudden death. The objective is to review the clinical presentation, histopathological spectrum, mortality and follow-up data of patients with cardiac tumors following surgery treatment over a period of 5 years. Methods:We retrospectively collected the medical records of all patients diagnosed of cardiac tumors in the period between January 2008 and December 2013 at the cardiac center of our university. Clinical histories, perioperative data, surgical findings, efficacy and follow-up data were reviewed in our study.Patients were divided into two groups according to site distribution of the tumors in the heart.Results: A total of 131 patients underwent surgical treatment of cardiac tumors were enrolled in this study, with a mean age of 51.39±16.37. The result of analysis showed that 79.47% (n=104) of the primary intracardiac tumors were benign, while primary malignant neoplasms accounted for 16.03% (n=21) of all patients, with the remainder (n=6, 4.6%) metastatic tumors transferred from other organs. Among all patients there were 2 in-hospital deaths and the survival rate in all patients at 1-year, 3-year and 5-year follow up was 83.20%, 78.62% and 66.41% respectively. Both patients with tumors in the left and right heart had similar basic characteristics except sex gender (P=0.002), BSA (P=0.045) and weight (P=0.033). Compared with patients with tumors in the right heart, patients with tumors in the left heart had significant higher CPB time (P<0.001), cross clamp time (P<0.001) and time of mechanical ventilation (P<0.001), and they also had longer ICU stay (P<0.001) but not total hospital stay (P=0.434).Conclusions: Surgical resection represents an effective protocol in treating cardiac tumors. Data in our study of cardiac tumors on frequency and allocation were consistent with previous reports which may provide useful clinical evidence on shared data, and data revealed that patients with malignant cardiac tumors had significant lower survival both in hospital and long-term follow-up.

show abstract

“…4,5,8 Echocardiogram sensitivity in detecting CAS can reach 75%; 9 advanced imaging such as cardiac magnetic resonance imaging adds great value in differentiating between benign and malignant masses. 10 However, a tissue biopsy is needed to confirm the diagnosis, either open biopsy for operable tumors or transvenous endomyocardial biopsy for inoperable tumors.…”

Section: Case Reportmentioning

confidence: 99%